相关实验视频

Updated: Apr 13, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

在高脂肪饮食诱导的肥胖小鼠中,E4bp4-Cyp3a11轴与体重波动有关

Shuoshuo Sun^1,2,3, Ruixiang Zhang^1,2, Yu Chen^1,2

¹Department of Endocrinology, Affiliated Hospital of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, People's Republic of China.

Nutrition & metabolism

|May 27, 2024

概括

体重减轻后肥胖小鼠的体重恢复显示,与持续肥胖相比,代谢障碍较轻. E4促进体结合蛋白4 (E4bp4) 和细胞染色体P450 3a11 (Cyp3a11) 轴可能在体重调节机制中发挥作用.

科学领域:

代谢学代谢学代谢学
肥胖研究的研究.
肝脏转录组学肝脏转录组学

背景情况:

重量恢复是控制肥胖的一个重大挑战.
了解体重波动期间的代谢变化对于有效的肥胖管理至关重要.
肝转录酶在减肥后体重恢复中的作用需要进一步研究.

研究的目的:

为了对肥胖小鼠的肝脏转录组进行分析,在体重减轻一段时间后体重恢复.
阐明这些代谢变化的特征和临床意义.
为了确定潜在的分子机制背后的重量调节.

主要方法:

在C57BL/6J小鼠中,高脂肪饮食 (HFD) 诱导了肥胖.
小鼠被分为体重增加 (WG),体重减轻 (WL) 和体重恢复 (WR) 组.
通过RNA测序和Western blot对E4bp4和Cyp3a11进行评估的体重,葡萄糖代谢,脂质概况,肝脏形态和肝脏转录组.

主要成果:

重量恢复小鼠 (WR) 与持续肥胖的小鼠 (WG) 相比,显示出较轻微的葡萄糖和脂质代谢障碍.
在WL和WR组与WG组相比,肝脂积累减少.
肝转录组分析显示了脂质代谢途径的显著变化,在WL和WR组中,E4bp4降低调节,Cyp3a11上调调节.

结论:

体重恢复的肥胖小鼠比持久肥胖的小鼠表现出不那么严重的代谢功能障碍.
在体重减轻和恢复后,在肝脏中观察到E4bp4的下调和Cyp3a11的上调.
建议E4bp4-Cyp3a11轴参与体重调节的代谢机制.

关键词:

在Cyp3a1111中使用.E4bp4 E4bp4 在线播放有高脂肪的饮食.肝脏肝脏肝脏肝脏肥胖问题肥胖问题

更多相关视频

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Published on: May 24, 2018

Assessing Whole-Body Lipid-Handling Capacity in Mice

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

相关概念视频

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...